Category: Cardiac ImplantsSyndicate content

Valve-in-valve surgery shows promise in new registry study

July 11, 2014 by Arezu Sarvestani

An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.

Medtronic and Edwards implants show promise in valve-in-valve treatment

New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.

More good news for Abbott's MitraClip in JACC study

July 11, 2014 by Arezu Sarvestani

Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.

More good news for Abbott's MitraClip

High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.

DC Devices secures another $34M for transcatheter cardiac shunt

July 2, 2014 by Arezu Sarvestani

Massachusetts-based DC Devices closed a $34 million Series D funding round in supports of its transcatheter InterAtrial Shunt Device.

DC Devices secures another $34M for transcatheter cardiac shunt

Bay State startup DC Device announced the successful close of a $34 million Series D financing round, hoping to use the funds to advance clinical evaluation of its InterAtrial Shunt Device.

The company aims to market the world's 1st minimally invasive device for treating diastolic heart failure, a market worth a potential $5 billion globally, according to a DC Device press release.

Boston Scientific's Watchman misses 1 of 2 efficacy goals in PREVAIL trial

July 1, 2014 by Arezu Sarvestani

Medtech titan Boston Scientific finally unveils the full results from its PREVAIL study, which was the subject of controversy at last year's ACC conference.

Boston Scientific's Watchman misses 1 of 2 efficacy goals in PREVAIL trial

Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Mitralign raises another $8M

June 20, 2014 by Brad Perriello

Mitralign adds another $8 million to its coffers a few months after closing enrollment on a clinical trial of its mitral valve repair device.

Mitralign raises another $8M

Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.

The Mitralign system is designed to deliver via catheter at least 1 pair of anchors that, when cinched together, help restore the heart's mitral valve to its natural shape in patients with functional mitral regurgitation, according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Cardiostim 2014: Medtronic treats 1st patients with tiny Micra pacemaker, Sorin touts 'SafeR' pacing

June 19, 2014 by Arezu Sarvestani

Medtronic unveils early results from the 1st patients implanted with the pill-sized Micra pacemaker and Sorin shows that its 'SafeR' mode of pacing prevents unnecessary shocks.

Cardiostim 2014: Medtronic treats 1st patients with tiny Micra pacemaker, Sorin touts 'SafeR' pacing

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA wants another panel hearing on Boston Scientific's Watchman anti-stroke device

June 17, 2014 by Brad Perriello

The FDA wants to convene another advisory panel on Boston Scientific's Watchman anti-stroke heart repair device, CFO Dan Brennan told investors today in Boston, saying the development pushes the approval timeline into 2015.

FDA wants another panel hearing on Boston Scientific's Watchman heart device

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp